Mechanism of antitumor drug action assessed by cytometry.
Traganos
Frank
F
Brander Cancer Research Institute, New York Medical College, Hawthorne, New York 10532, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000378:metabolism; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016213:Cyclins / Q000378:metabolism; D004247:DNA / Q000032:analysis / Q000096:biosynthesis; D005434:Flow Cytometry / Q000379:methods*; D005456:Fluorescent Dyes / Q000737:chemistry; D006657:Histones / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D015999:Multivariate Analysis; D016160:Retinoblastoma Protein / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D016213:Cyclins; D005456:Fluorescent Dyes; C468783:H2AX protein, human; D006657:Histones; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D004247:DNA; D001973:Bromodeoxyuridine